Developing natural nano-platforms with high biocompatibility and natural targeting ability
represents great significance for drug delivery. High-density lipoprotein (HDL), a natural lipid …

Immunotherapy has revolutionised the treatment of oncological patients, but its application
in various endocrine tumours is rather limited and is mainly used when conventional …

Context Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor
prognosis in advanced stages. While therapies targeting the checkpoint molecules …

The response rate of advanced adrenocortical carcinoma (ACC) to standard chemotherapy
with mitotane and etoposide/doxorubicin/cisplatin (EDP-M) is unsatisfactory, and benefit is …

Background Adrenocortical carcinoma is a rare malignancy with poor response to systemic
chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma …

In the past decade, there have been a record number of oncology therapy approvals by the
US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) …

Background Adrenocortical carcinoma has a poor prognosis and multiple clinical,
pathological, and treatment variables. Currently, we lack a prognostic and treatment …

Abstract Importance Mitotane (Lysodren, o, p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-
2, 2-dichloroethane)] is currently the only United States Food and Drug Administration and …

Adrenocortical carcinoma (ACC) patients with glucocorticoid excess have been reported to
be associated with decreased tumor-infiltrating immune cells, but the effects of in situ …

Objective Adrenal cortical carcinoma (ACC) is a rare malignancy with a generally poor but
heterogeneous prognosis, especially depending on the tumour stage at diagnosis …